Literature DB >> 19340883

New insights into the biotransformation and pharmacokinetics of oxaliplatin.

Elin Jerremalm1, Inger Wallin, Hans Ehrsson.   

Abstract

Oxaliplatin is used primarily in the treatment of metastatic colorectal cancer. In this minireview, we discuss potentially important biotransformation pathways in light of its short elimination half-life in vivo. We also highlight new information achieved using a selective analytical technique to measure intact oxaliplatin in pharmacokinetic studies (comprising intravenous, intraperitoneal, and intrahepatic administration) and compare to results obtained by measurements of total platinum. The use of selective analytical techniques is strongly recommended giving kinetic parameters of the parent compound and not only to a complex mixture of platinum containing endogenous compounds. (c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19340883     DOI: 10.1002/jps.21732

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  16 in total

Review 1.  Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.

Authors:  Loek A W de Jong; Fortuné M K Elekonawo; Philip R de Reuver; Andre J A Bremers; Johannes H W de Wilt; Frank G A Jansman; Rob Ter Heine; Nielka P van Erp
Journal:  Br J Clin Pharmacol       Date:  2018-10-25       Impact factor: 4.335

2.  Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma.

Authors:  She-Gan Gao; Rui-Nuo Jia; Xiao-Shan Feng; Xuan-Hu Xie; Tan-You Shan; Li-Xian Pan; Na-Sha Song; Yu-Feng Wang; Kai-Li Ding; Li-Dong Wang
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

3.  Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature.

Authors:  Julia Quidde; Marc Azémar; Carsten Bokemeyer; Dirk Arnold; Alexander Stein
Journal:  Ther Adv Med Oncol       Date:  2016-03-17       Impact factor: 8.168

4.  Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives.

Authors:  Kazuhiko Hanada; Makoto Suda; Norihito Kanai; Hiroyasu Ogata
Journal:  Pharm Res       Date:  2010-06-15       Impact factor: 4.200

5.  Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo.

Authors:  Eun Jung Park; Junhyun Ahn; Sharif Md Abuzar; Kyung Su Park; Sung-Joo Hwang; Seung Hyuk Baik
Journal:  Ann Surg Oncol       Date:  2022-08-30       Impact factor: 4.339

6.  Designing a Mucoadhesive ChemoPatch to Ablate Oral Dysplasia for Cancer Prevention.

Authors:  Xiaoqin Liu; Qian Li; Yang Wang; Madeleine Crawford; Parnit K Bhupal; Xiuqing Gao; Huan Xie; Dong Liang; Yi-Shing L Cheng; Xiaohua Liu; Robert Y L Tsai
Journal:  Small       Date:  2022-05-19       Impact factor: 15.153

7.  Is Platinum Present in Blood and Urine from Treatment Givers during Hyperthermic Intraperitoneal Chemotherapy?

Authors:  Sara Näslund Andréasson; Helena Anundi; Sig-Britt Thorén; Hans Ehrsson; Haile Mahteme
Journal:  J Oncol       Date:  2010-07-01       Impact factor: 4.375

8.  P2X7 Cell Death Receptor Activation and Mitochondrial Impairment in Oxaliplatin-Induced Apoptosis and Neuronal Injury: Cellular Mechanisms and In Vivo Approach.

Authors:  France Massicot; Guillaume Hache; Ludivine David; Dominique Chen; Charlotte Leuxe; Laure Garnier-Legrand; Patrice Rat; Olivier Laprévote; François Coudoré
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

9.  A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.

Authors:  Hristo P Varbanov; Simone Göschl; Petra Heffeter; Sarah Theiner; Alexander Roller; Frank Jensen; Michael A Jakupec; Walter Berger; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2014-07-30       Impact factor: 7.446

10.  Interaction of classical platinum agents with the monomeric and dimeric Atox1 proteins: a molecular dynamics simulation study.

Authors:  Xiaolei Wang; Chaoqun Li; Yan Wang; Guangju Chen
Journal:  Int J Mol Sci       Date:  2013-12-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.